Cytokinetics, Incorporated cash flow to debt ratio of -39.71% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Cytokinetics, Incorporated's free cash flow has decreased 33.77% from $-399.80M last year to $-534.82M, signaling decreasing performance

Cytokinetics, Incorporated's debt to equity ratio is -1.56, signaling that the company spent its equity and risk bankruptcy.

Cytokinetics, Incorporated's debt to equity ratio is -1.56, signaling that the company spent its equity and risk bankruptcy.

Cytokinetics, Incorporated has negative EBITDA, making leverage ratio unreliable

Cytokinetics, Incorporated's interest coverage ratio is -5.60, which means that the company struggles to meet interest obligations, signaling financial risk.

Cytokinetics, Incorporated's profit margin has increased (-75.43%) in the last year from -3.19K% to -784.02%, signaling increasing performance

Cytokinetics, Incorporated's short-term assets of $916.98M exceed its short-term liabilities of $202.45M

Cytokinetics, Incorporated's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Cytokinetics, Incorporated's return on equity of 139.66%, is higher than 15.00%, indicating good performance

Cytokinetics, Incorporated's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Cytokinetics, Incorporated had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Cytokinetics, Incorporated has negative free cash flow, indicating the company is burning cash rather than generating it

Cytokinetics, Incorporated has negative free cash flow, indicating cash burn

Cytokinetics, Incorporated's yearly earnings has decreased 33.15% since last year from $-589.53M to $-784.96M, signaling decreasing performance

Cytokinetics, Incorporated's yearly revenue has increased 376.56% since last year from $18.47M to $88.04M, signaling increasing performance

ROIC -56.16% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Cytokinetics, Incorporated's 3-year revenue CAGR of -2.36% is negative, indicating declining revenue over the past 3 years

Cytokinetics, Incorporated had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Cytokinetics, Incorporated had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Cytokinetics, Incorporated has insufficient data to evaluate this check.

Cytokinetics, Incorporated has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cytokinetics, Incorporated is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Cytokinetics, Incorporated has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Cytokinetics, Incorporated has insufficient data to evaluate this check.

Cytokinetics, Incorporated has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cytokinetics, Incorporated has negative shareholder equity; price-to-book is not meaningful and the check fails

Cytokinetics, Incorporated has a price-to-sales ratio of 95.45x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue